Efficient sequence of therapy for advanced and metastatic endometrial cancer
Historical standard of the first line endometrial cancer therapy was combination of paclitaxel and carboplatin. In more than a half of patients with advanced endometrial cancer receiving this combination, disease progression is observed after 2 years. Use of paclitaxel + carboplatin combination in a...
Saved in:
| Main Author: | A. A. Rumyantsev |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2022-09-01
|
| Series: | Опухоли женской репродуктивной системы |
| Subjects: | |
| Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/978 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Combination of pembrolizumab and lenvatinib in second-line therapy for MSS/pMMR advanced endometrial cancer: literature review and a case report
by: A. D. Darenskaya, et al.
Published: (2024-01-01) -
The long-term clinical efficacy and safety of lenvatinib plus pembrolizumab in endometrial cancer: data from routine clinical practice in Russia
by: A. E. Protasova, et al.
Published: (2024-11-01) -
Clinical and morphological features in patients with advanced endometrial cancer treated with immunotargeting therapy
by: L. A. Kolomiets, et al.
Published: (2023-08-01) -
Possible applications for combined lenvatinib and pembrolizumab in advanced endometrial carcinoma
by: K. V. Menshikov, et al.
Published: (2023-01-01) -
COMBINATION OF LENVATINIB AND PEMBROLISUMAB IN THE TREATMENT OF ADVANCED ENDOMETRIAL CANCER: A CASE REPORT
by: O. N. Churuksaeva, et al.
Published: (2021-03-01)